Progression Issues Surface With NSCLC Immunotherapy – OncLive (blog)
OncLive (blog) |
Progression Issues Surface With NSCLC Immunotherapy
OncLive (blog) Pseudoprogression, which has been observed in less than 10% of patients with lung cancer, occurs when an early scan shows tumor growth that may be due to a delayed benefit of the immunotherapy treatment or inflammation of the tumor as T cells become … |
